StockNews.AI
BBLG
StockNews.AI
74 days

Bone Biologics Announces 1-for-6 Reverse Stock Split

1. Bone Biologics will execute a 1-for-6 reverse stock split on June 10, 2025. 2. Shareholder approval granted the board authority for the split range of 1-for-2.5 to 1-for-10. 3. Post-split, stock ownership percentages remain unchanged, but share count will decrease. 4. The company focuses on bone regeneration in spinal fusion; partnerships are ongoing. 5. Risks may affect predicted outcomes from the reverse split, per forward-looking statements.

5m saved
Insight
Article

FAQ

Why Neutral?

Reverse splits often stabilize stock prices in the short term but do not inherently indicate growth or decline. Historical cases show stocks like Citigroup initially reacted positively but later struggled long-term.

How important is it?

The reverse stock split could affect liquidity and investor perception, potentially impacting trading volume and volatility, but the long-term direction remains uncertain due to the company's ongoing risk factors.

Why Short Term?

The immediate effect of the stock split may stabilize price, but long-term performance depends on underlying business execution and market conditions. For example, stocks commonly fluctuate after the initial split announcement.

Related Companies

CITITSLAAAPL
- BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,” at the market open on June 10, 2025. At the Company’s annual meeting of stockholders held on May 30, 2025, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to implement a reverse stock split in a range of 1-for-2.5 to 1-for-10, and granted the board of directors the authority to implement and determine the exact split ratio within such range, which was subsequently set by the board at 1-for-6. Following the reverse stock split, the new CUSIP number of the common stock will be 098070600, with the par value per share of common stock remaining at $0.001. A proportionate adjustment will be made to the per-share exercise prices and number of shares issuable under all outstanding warrants and equity awards. When the reverse stock split becomes effective, every six shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. Each stockholder’s percentage ownership interest in Bone Biologics will remain unchanged after the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share of common stock. The number of authorized shares of common stock of the Company will remain the same following the reverse stock split. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements regarding the timing, implementation, and success of the reverse stock split, as well as statements containing the words “plan,” “will,” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. More News From Bone Biologics Corporation

Related News